MedElevator
Войти в исследования PharmacoEconomics - open · 2026
Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zarkadoulas Eleftherios, Silva Fábio, Alves Joana, Madeira Francisco, Postma Maarten J
Аннотация
BACKGROUND AND OBJECTIVES: Herpes zoster (HZ) and associated complications comprise a considerable public health burden in older adults. This study aimed to evaluate the cost-effectiveness of recombinant zoster vaccine (RZV) versus no vaccine for the prevention of HZ in older adults in Portugal.
METHODS: A static multicohort Markov model (ZONA) was adapted to the Portuguese context. The base-case compared RZV with no vaccination in a hypothetical cohort of 1 million adults aged ≥65 years. Real-world data were used for first-dose coverage (56.1%) and second-dose completion (67.2%), with vaccine efficacy and waning based on 11-year follow-up data. Outcomes were calculated over a lifetime horizon from the societal perspective, with a 4% discount applied to costs and quality-adjusted life years (QALYs). In the base-case, HZ incidence was based on previously reported European data. Sensitivity analyses were performed, and a scenario analysis explored the impact of alternative HZ incidence rates based on recent Portuguese data.
RESULTS: Over a lifetime horizon, RZV was estimated to prevent 45,551 HZ cases, 9056 post-herpetic neuralgia (PHN) cases, 5580 cases with other non-PHN complications, and 6 HZ deaths. The incremental cost-effectiveness ratio (ICER) from the societal perspective was €48,707 per QALY gained, below a hypothetical willingness-to-pay threshold of two times the gross domestic product per capita per QALY gained (equivalent to €62,200). This base-case ICER was most sensitive to the annual incidence of initial HZ. In the scenario analysis, exploring higher HZ incidence based on Portuguese data, the estimated ICER was €41,877 per QALY gained. In both the base-case and the scenario analyses, ICERs were lowest in individuals aged 65-69 years, with ICERs ranging from €36,207 to €42,700 per QALY gained, in the scenario analysis and base case, respectively.
CONCLUSIONS: RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.
METHODS: A static multicohort Markov model (ZONA) was adapted to the Portuguese context. The base-case compared RZV with no vaccination in a hypothetical cohort of 1 million adults aged ≥65 years. Real-world data were used for first-dose coverage (56.1%) and second-dose completion (67.2%), with vaccine efficacy and waning based on 11-year follow-up data. Outcomes were calculated over a lifetime horizon from the societal perspective, with a 4% discount applied to costs and quality-adjusted life years (QALYs). In the base-case, HZ incidence was based on previously reported European data. Sensitivity analyses were performed, and a scenario analysis explored the impact of alternative HZ incidence rates based on recent Portuguese data.
RESULTS: Over a lifetime horizon, RZV was estimated to prevent 45,551 HZ cases, 9056 post-herpetic neuralgia (PHN) cases, 5580 cases with other non-PHN complications, and 6 HZ deaths. The incremental cost-effectiveness ratio (ICER) from the societal perspective was €48,707 per QALY gained, below a hypothetical willingness-to-pay threshold of two times the gross domestic product per capita per QALY gained (equivalent to €62,200). This base-case ICER was most sensitive to the annual incidence of initial HZ. In the scenario analysis, exploring higher HZ incidence based on Portuguese data, the estimated ICER was €41,877 per QALY gained. In both the base-case and the scenario analyses, ICERs were lowest in individuals aged 65-69 years, with ICERs ranging from €36,207 to €42,700 per QALY gained, in the scenario analysis and base case, respectively.
CONCLUSIONS: RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.